Hologic, Inc.: insider trading
1,545 trades by 57 directors, officers and 10% owners since 2009, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$0
0 sales by 0 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$0
0 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (57)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Amy McBride WendellDirector | 0 | — | — | |
| Anne M. LiddyGeneral Counsel | 0 | — | — | |
| Benjamin Jordan CohnPrincipal Accounting Officer | 0 | — | — | |
| Brandon SchnittkerPresident, GYN Surgical | 0 | — | — | |
| Charles J. DockendorffDirector | 0 | — | — | |
| Christiana StamoulisDirector | 0 | — | — | |
| Diana De WaltSVP, Human Resources | 0 | — | — | |
| Essex D. MitchellChief Operating Officer | 0 | — | — | |
| Jan VerstrekenGroup President, International | 0 | — | — | |
| Jennifer M. SchneidersPresident, Diag. Solutions | 0 | — | — | |
| Karleen Marie ObertonChief Financial Officer | 0 | — | — | |
| Ludwig HantsonDirector | 0 | — | — | |
| Mark W. HorvathPresident, Breast & Skeletal | 0 | — | — | |
| Martin D. MadausDirector | 0 | — | — | |
| Nanaz MohtashamiDirector | 0 | — | — | |
| Stacey D. StewartDirector | 0 | — | — | |
| Stephen P. MacmillanChairman, President and CEO, Director | 0 | — | — | |
| Wayde D. McMillanDirector | 0 | — | — | |
| Erik S. AndersonDiv. Pres., Breast & Skeletal | 23,231 | — | — | |
| John M. GriffinGeneral Counsel | 182,514 | — | — | |
| Scott T. GarrettDirector | 48,611 | — | — | |
| Sally CrawfordDirector | 132,927 | — | — | |
| Peter Paul DunneSVP, Human Resources | 10,643 | — | — | |
| Elisabeth A. HellmannSVP, Human Resources | 9,574 | — | — | |
| Namal NawanaDirector | 18,221 | — | — | |
| Kevin R. ThornalGroup Pres, Global Diagnostics | 62,368 | — | — | |
| Sean S. DaughertyGroup President, BSH & Surg. | 49,091 | — | — | |
| Allison P. BeboSVP, Human Resources | 35,680 | — | — | |
| Peter J. Valenti IIIDivision Pres., Breast Health | 59,991 | — | — | |
| Thomas A. WestDiv President & GM, Diagnostic | 55,753 | — | — | |
| Robert W. McMahonChief Financial Officer | 112,244 | — | — | |
| Eric B. ComptonCOO | 107,560 | — | — | |
| Elaine UllianDirector | 27,302 | — | — | |
| Lawrence M. LevyDirector | 32,615 | — | — | |
| Christopher J. CoughlinDirector | 7,633 | — | — | |
| Nancy LeamingDirector | 55,595 | — | — | |
| David R. Lavance Jr.Director | 9,362 | — | — | |
| Jonathan ChristodoroDirector | 12,445 | — | — | |
| Samuel J. MerksamerDirector | 12,445 | — | — | |
| Wayne WilsonDirector | 42,487 | — | — | |
| Jay A. SteinChief Technical Officer | 201,648 | — | — | |
| Claus EgstrandSVP and GM, International | 3,150 | — | — | |
| Carl C. Icahnno longer subject to Sec. 16 | — | — | — | |
| Mark J. CaseySVP, CAO, GC & Secretary | 14,725 | — | — | |
| Roger D. MillsGSVP & GM Service & Operations | 58,823 | — | — | |
| Rohan HastieGroup SVP & GM Diagnostics | 2,857 | — | — | |
| Glenn P. MuirExecutive VP and CFO | 815,306 | — | — | |
| Robert H. LavalleeSVP, Chief Accounting Officer | 11,341 | — | — | |
| David HardingGroup VP & GM, Women's Health | 53,645 | — | — | |
| David J. BradySVP, Human Resources | 25,677 | — | — | |
| John W. CummingPresident and CEO | 8,565 | — | — | |
| Robert CascellaCEO and President, Director | 400,655 | — | — | |
| Peter SoltaniSVP & GM, Women's Health | 42,625 | — | — | |
| Carl HullSVP and GM of Diagnostics | 61,674 | — | — | |
| Steve S. WilliamsonSVP, GYN Surgical | 41,721 | — | — | |
| John R. PekarskySVP, Sales & Strategic Account | 36,338 | — | — | |
| Howard Doran Jr.SVP, Diagnostics Products | 38,502 | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Martin D. MadausDirector | Buyindirect | +5,445 | $55.24 | $301 K | 5,445 | Form 4 |
| filed | Charles J. DockendorffDirector | Buy | +13,000 | $38.80 | $504 K | 17,776 | Form 4 |
| filed | Amy McBride WendellDirector | Buy | +5,200 | $38.43 | $200 K | 10,297 | Form 4 |
| filed | Namal NawanaDirector | Buy | +6,600 | $37.88 | $250 K | 6,954 | Form 4 |
| filed | Eric B. ComptonCOO | Buy | +795 | $26.39 | $21 K | 795 | Form 4 |
| filed | Elaine UllianDirector | Buy | +7,900 | $25.36 | $200 K | 7,900 | Form 4 |
| filed | Stephen P. MacmillanPresident and CEO, Director | Buy | +37,100 | $21.60 | $801 K | 237,500 | Form 4 |
| filed | Stephen P. MacmillanPresident and CEO, Director | Buy | +1,500 | $20.98 | $31 K | 200,400 | Form 4 |
| filed | Stephen P. MacmillanPresident and CEO, Director | Buy | +107,816 | $20.81 | $2.2 M | 198,900 | Form 4 |
| filed | Stephen P. MacmillanPresident and CEO, Director | Buy | +91,084 | $20.75 | $1.9 M | 91,084 | Form 4 |
| filed | Peter SoltaniSVP, Breast Health | Buy | +4,000 | $12.67 | $51 K | 51,980 | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice